Status:
COMPLETED
Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Lead Sponsor:
University of Maryland, Baltimore
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-65 years
Brief Summary
Multiple Sclerosis (MS) is an autoimmune disorder of the central nervous system. In MS, inflammation is known to attack areas of the brain, spinal cord, and optic nerves; resulting in disability. Curr...
Detailed Description
Twenty-two (22) participants will be recruited from the University of Maryland Center for Multiple Sclerosis Treatment and Research. Participants will be included if they are aged 18-65, have a diagno...
Eligibility Criteria
Inclusion
- A diagnosis of relapsing or primary progressive multiple sclerosis according to revised 2010 McDonald Criteria
- Ages 18 to 65, inclusive
- Have been prescribed ocrelizumab by their treating physician for treatment of multiple sclerosis, with the 1st infusion to occur within 30 days of enrollment
Exclusion
- Inability to provide informed consent
- Inability to undergo MRI due to implantable devices or metallic foreign bodies considered unsafe in the MRI magnet
- Known severe allergic reaction (anaphylaxis) in the past to gadolinium contrast
- A current diagnosis of severe kidney failure and/or use of hemodialysis
- Currently pregnant or lactating
- History of a seizure disorder
Key Trial Info
Start Date :
September 24 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 25 2023
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03396822
Start Date
September 24 2018
End Date
May 25 2023
Last Update
February 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland School of Medicine
Baltimore, Maryland, United States, 21201